{"product_id":"nyxh-vrio-analysis","title":"Nyxoah S.A. (NYXH): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Nyxoah S.A. (NYXH) truly built to last? Our VRIO analysis cuts straight to the core of its competitive edge, revealing that its current strengths are summarized by: \u0026amp;O4\u0026amp;. Dive in now to see exactly which resources give this business its staying power - or where the vulnerabilities lie.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 1. Genio System's Unique Bilateral, Leadless Design (Technology)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at a technology that just secured a major regulatory win in the US market, which is a huge signal for its competitive standing. The Genio System’s design is the core of its current and future value proposition, so let’s break down its competitive durability using the VRIO lens.\u003c\/p\u003e\n\u003cp\u003eThe system’s core advantage is its unique engineering, which has translated into compelling clinical proof points that support its recent FDA clearance on \u003cstrong\u003eAugust 8, 2025\u003c\/strong\u003e, for patients with an Apnea-Hypopnea Index (AHI) between \u003cstrong\u003e15\u003c\/strong\u003e and \u003cstrong\u003e65\u003c\/strong\u003e. This is not just a marginal improvement; it’s a structural difference from older models.\u003c\/p\u003e\n\u003cp\u003eHere’s the quick math on the clinical validation that underpins its Value:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eGenio System Result (12 Months)\u003c\/td\u003e\n\u003ctd\u003eContext\/Benchmark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian AHI Reduction (Supine)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAddresses a key challenge, as supine sleep is often when obstructions are worst.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian AHI Reduction (All Positions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOverall efficacy across the full night's sleep.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAHI Responder Rate (Sher Criteria)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePrimary endpoint met for FDA submission.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients with AHI \u0026lt; 15\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e82.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates transition from moderate\/severe to mild or better OSA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Satisfaction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh adherence signal, crucial for long-term adoption.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eWhat this estimate hides is that while the Q3 2025 revenue was only \u003cstrong\u003e€2.0 million\u003c\/strong\u003e, the FDA approval and subsequent payer coverage (like United Healthcare and Blue Cross Blue Shield) are the real drivers of future value, justifying the high operating expenses seen in the period.\u003c\/p\u003e\n\u003cp\u003eThe VRIO assessment for this core technology is laid out below:\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e High. Achieves a \u003cstrong\u003e66.6%\u003c\/strong\u003e median AHI reduction while supine, plus it is \u003cstrong\u003e1.5T\u003c\/strong\u003e and \u003cstrong\u003e3T\u003c\/strong\u003e MRI compatible, offering patient convenience over implanted batteries.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e High. The combination of bilateral stimulation, leadless design, and external power source is unique; competitors often rely on unilateral stimulation or implanted power sources.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Costly\/Difficult. The specific engineering is protected by patents, making direct replication slow and requiring significant R\u0026amp;D investment to match the clinical profile.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company is clearly organized around this platform, evidenced by successfully navigating the complex FDA PMA process to gain approval on \u003cstrong\u003eAugust 8, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe resulting competitive advantage is clear. The technology is not just a temporary edge; it’s built into the device architecture. If onboarding takes 14+ days, churn risk rises, but the tech itself offers a durable moat.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The unique, non-implanted, bilateral stimulation mechanism, backed by robust clinical data (like the \u003cstrong\u003e70.8%\u003c\/strong\u003e overall AHI reduction), creates a durable barrier to entry for rivals attempting to match both features and efficacy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 2. U.S. FDA Pre-Market Approval (PMA) for Genio System\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Unlocks the massive U.S. market, which is the primary driver for future revenue expectations post-August 8, 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. It is the first and only bilateral HGNS therapy approved in the U.S. as of late 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Regulatory hurdles and the need for successful pivotal trials (like DREAM) are massive barriers to entry.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company immediately kicked off U.S. commercial launch in October 2025, showing readiness.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Regulatory exclusivity, even if temporary, provides a significant first-mover advantage in the U.S.\u003c\/p\u003e\n\u003cp\u003eThe U.S. Food and Drug Administration (FDA) approved the Genio System on \u003cstrong\u003eAugust 8, 2025\u003c\/strong\u003e, for a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) with an Apnea-Hypopnea Index (AHI) between \u003cstrong\u003e15\u003c\/strong\u003e and \u003cstrong\u003e65\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe approval was supported by the DREAM pivotal study, which demonstrated efficacy across key endpoints:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Endpoint\u003c\/td\u003e\n\u003ctd\u003eResult\/Metric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAHI Responder Rate (Intent-To-Treat)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e73 subjects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eODI Responder Rate (Intent-To-Treat)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e82 subjects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian AHI Reduction (All Positions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt 12 months vs. baseline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian AHI Reduction (Supine Position)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAt 12 months vs. baseline\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubjects with AHI Score Below 15\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e82.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOf all DREAM subjects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Satisfaction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported at 12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe Genio system's unique design features contributing to its rarity include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBilateral stimulation capability.\u003c\/li\u003e\n\u003cli\u003eLeadless, battery-free implant design.\u003c\/li\u003e\n\u003cli\u003eCompatibility with full-body \u003cstrong\u003e1.5T\u003c\/strong\u003e and \u003cstrong\u003e3T\u003c\/strong\u003e MRI scans.\u003c\/li\u003e\n\u003cli\u003eExternally powered and controlled wearable component that is fully upgradable, avoiding repeat surgeries for technology updates or battery replacements.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOrganizational readiness for the U.S. market was demonstrated by the immediate commercial rollout, with the first U.S. commercial patients implanted on \u003cstrong\u003eOctober 6, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company achieved successful coverage from major payors, including \u003cstrong\u003eCMS\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eKey performance indicators being monitored include the number of surgeons trained, Value Analysis Committee (VAC) submissions, volume of prior authorization requests, and number of accounts opened.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe potential value is underscored by market projections, with the global OSA neuromodulation market projected to grow at a Compound Annual Growth Rate (CAGR) of \u003cstrong\u003e16.2%\u003c\/strong\u003e from 2025 to 2035, expanding from \u003cstrong\u003e$794.9 million in 2024\u003c\/strong\u003e to \u003cstrong\u003e$4.07 billion by 2035\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe U.S. market is estimated to hold a potential revenue of \u003cstrong\u003e$650M\u003c\/strong\u003e for Genio.\u003c\/li\u003e\n\u003cli\u003eNyxoah reported gross margins of \u003cstrong\u003e61.8%\u003c\/strong\u003e in \u003cstrong\u003eQ1 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 3. DREAM Pivotal Study Efficacy Data\n\u003c\/h2\u003e\n\u003cp\u003eThe DREAM pivotal study data, published in the \u003cem\u003eJournal of Clinical Sleep Medicine\u003c\/em\u003e, provides quantifiable evidence of the Genio System's performance.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Provides high-quality, peer-reviewed proof of efficacy, showing 90% patient satisfaction and strong AHI reduction across positions.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe study enrolled 115 patients with a mean baseline AHI of 28.0, mean ODI of 27.0, and mean BMI of 28.5.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eEfficacy Metric\u003c\/td\u003e\n\u003ctd\u003eResult at 12 Months\u003c\/td\u003e\n\u003ctd\u003eStatistical Significance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Satisfaction\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e90%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian AHI Reduction (All Positions)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e70.8%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian AHI Reduction (Supine Position)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e66.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAHI Responder Rate (ITT, Sher Criteria)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ep=0.002\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eODI Responder Rate (ITT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e71.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ep\u0026lt;0.001\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: High. It is the only therapy with such clinical evidence from a large, multicenter, prospective study showing efficacy regardless of sleeping position.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMedian AHI reduction of \u003cstrong\u003e70.8%\u003c\/strong\u003e across all sleeping positions was demonstrated.\u003c\/li\u003e\n\u003cli\u003eSnoring score reduced from 83.5% at baseline to 30.4% at 12 months.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Medium. Competitors can run trials, but replicating the specific, positive outcomes and publication in the Journal of Clinical Sleep Medicine is tough.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAdherence and quality-of-life improvements support the data's strength:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDevice usage exceeded 70% of nights in 85.9% of participants.\u003c\/li\u003e\n\u003cli\u003eNightly device usage met the CPAP compliance threshold in 84.3% of participants completing diary entries in the 3 months preceding the 12-month visit.\u003c\/li\u003e\n\u003cli\u003eEpworth Sleepiness Score improved by a mean of 3.4 points.\u003c\/li\u003e\n\u003cli\u003eFunctional Outcomes of Sleep Questionnaire (FOSQ) showed a mean increase of 2.3 points.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: High. This data is the foundation for all U.S. marketing and payer negotiations.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe study results support the FDA premarket approval submission, which was granted in August 2025.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety Metric\u003c\/td\u003e\n\u003ctd\u003eResult\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSerious Adverse Event (SAE) Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal SAEs\u003c\/td\u003e\n\u003ctd\u003e11 in 10 subjects\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice-Related SAEs\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExplants\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Temporary. While strong now, clinical data can be surpassed by newer, better studies from competitors over time.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe data supports the Genio system's bilateral stimulation for a wider spectrum of OSA patients, including those with Complete Concentric Collapse (CCC) who are contraindicated for competitors' therapy.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 4. Expanded CE Mark for Complete Concentric Collapse (CCC) Patients\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBroadens the addressable patient pool in Europe beyond what competitors can treat, as CCC patients were previously contraindicated. The CE-Mark indication approval for Complete Concentric Collapse (CCC) patients was granted on \u003cstrong\u003eOctober 4, 2021\u003c\/strong\u003e, following positive outcomes from the BETTER SLEEP study. This approval is estimated to expand the total addressable market by at least \u003cstrong\u003e30%\u003c\/strong\u003e. CCC patients represented \u003cstrong\u003e42.9%\u003c\/strong\u003e of the BETTER SLEEP study population. In the U.S., CCC patients are noted to represent more than \u003cstrong\u003e30%\u003c\/strong\u003e of OSA patients. The European market for OSA treatments is estimated to have a total addressable market of at least \u003cstrong\u003e515,000 patients\u003c\/strong\u003e, with an annual opportunity of approximately \u003cstrong\u003e€10 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMedium. This specific indication expansion is unique in the European market as of late \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMedium. Requires specific clinical data (BETTER SLEEP study) and regulatory navigation, which is not easily copied. The BETTER SLEEP trial demonstrated a statistically significant mean reduction in Apnea Hypopnea Index (AHI) in the CCC patient subgroup.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMedium. The company has successfully integrated this expanded indication into its European commercial strategy. For the full year ending December 31, 2024, Nyxoah's gross margin was \u003cstrong\u003e66%\u003c\/strong\u003e, with projected sales for 2025 reaching \u003cstrong\u003e€37.0 million\u003c\/strong\u003e, anticipating expansion impact.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary. Competitors are likely working to gain similar expanded indications in the EU.\u003c\/p\u003e\n\u003cp\u003eKey Statistics Related to CCC Indication Expansion:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Source Study\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCE Mark CCC Approval Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eOctober 4, 2021\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDEKRA Notified Body Approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated TAM Expansion in Europe\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAt least 30%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCEO Statement following approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCCC Prevalence in BETTER SLEEP Study\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e42.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBETTER SLEEP Study Population\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEstimated US CCC Patient Prevalence\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eMore than 30%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUS Market Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean OSA TAM (Annual Opportunity)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€10 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal European Market Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean OSA TAM (Patient Count)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e515,000 patients\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eTotal European Market Estimate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupporting Data from Clinical Outcomes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMean AHI reduction in CCC patient subgroup demonstrated in the BETTER SLEEP study.\u003c\/li\u003e\n\u003cli\u003eIn a separate investigator-sponsored case series for CCC patients, results showed an average AHI decrease of \u003cstrong\u003e73%\u003c\/strong\u003e and Epworth Sleepiness Scale (ESS) decrease of \u003cstrong\u003e58%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 5. Early U.S. Commercialization Infrastructure\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows the company to immediately convert FDA approval into revenue, with \u003cstrong\u003e€2.0 million\u003c\/strong\u003e in Q3 2025 revenue signaling early traction.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. While others have sales teams, Nyxoah has successfully trained surgeons and secured initial hospital approvals for a new device. Leading indicators include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTrained \u003cstrong\u003e24-36 surgeons each weekend\u003c\/strong\u003e through weekly training sessions.\u003c\/li\u003e\n\u003cli\u003eSubmitted nearly \u003cstrong\u003e20\u003c\/strong\u003e prior authorizations within the first 10 days of launch.\u003c\/li\u003e\n\u003cli\u003eSecured reimbursement with Medicare and private payers, achieving a \u003cstrong\u003e100%\u003c\/strong\u003e approval rate on prior authorization submissions from United Healthcare, Blue Cross Blue Shield, and Anthem.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium. Building a specialized sales force and training network takes time and capital, which they have already spent. The commercial team comprises \u003cstrong\u003e50-55\u003c\/strong\u003e personnel, including \u003cstrong\u003e25\u003c\/strong\u003e territory managers focused on high-volume accounts.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The immediate launch in October 2025 shows the organization was structured to execute on the approval. The company targeted approximately \u003cstrong\u003e400\u003c\/strong\u003e high-volume AGNS implanting sites across the U.S.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Competitors can hire and train, but Nyxoah has the current lead in surgeon adoption.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€2.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€1.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYear-over-Year Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e56%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e62.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Loss\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€24.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€15.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Position (End of Period)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€22.5 million\u003c\/strong\u003e (Sep 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe U.S. commercialization infrastructure is supported by the following financial and operational milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFirst commercial implants completed in \u003cstrong\u003eSeptember 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnticipated global revenue for Q4 2025 between \u003cstrong\u003e€3.4 million\u003c\/strong\u003e and \u003cstrong\u003e€3.6 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCash, cash equivalents and financial assets decreased from \u003cstrong\u003e€43.0 million\u003c\/strong\u003e at the end of June 30, 2025, to \u003cstrong\u003e€22.5 million\u003c\/strong\u003e on September 30, 2025.\u003c\/li\u003e\n\u003cli\u003eReimbursement secured utilizing CPT code \u003cstrong\u003e64568\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 6. Widespread Payer Coverage, Including CMS\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eRemoves a major barrier to adoption in the U.S. by securing coverage from major payors, including the Centers for Medicare \u0026amp; Medicaid Services (CMS).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePayer Setting\u003c\/th\u003e\n\u003cth\u003eCPT Code\u003c\/th\u003e\n\u003cth\u003e2026 Reimbursement Amount\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Increase (vs. 2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital Outpatient Department (HOPD)\u003c\/td\u003e\n\u003ctd\u003e64568\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$45,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmbulatory Surgery Centers (ASC) Facility\u003c\/td\u003e\n\u003ctd\u003e64568\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$42,373\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e58%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eInitial U.S. commercial implants completed: \u003cstrong\u003e5\u003c\/strong\u003e implants in one week (October 2025).\u003c\/p\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eHigh. Achieving CMS coverage for a novel device is a significant, hard-won milestone in MedTech.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eHigh. Payer negotiations are opaque and relationship-driven; this coverage is not easily replicated.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh. This coverage is a direct result of successful health economics and reimbursement team efforts.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Revenue: \u003cstrong\u003e€2.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenue Year-over-Year Growth: \u003cstrong\u003e56%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash, Cash Equivalents, and Financial Assets (September 30, 2025): \u003cstrong\u003e€22.5 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCash, Cash Equivalents, and Financial Assets (June 30, 2025): \u003cstrong\u003e€43.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Operating Loss: \u003cstrong\u003e€24.4 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained. Once secured, payer contracts create a long-term revenue stream that is difficult for rivals to match quickly.\u003c\/p\u003e\n\u003cp\u003eObstructive Sleep Apnea (OSA) market projected CAGR through 2030: \u003cstrong\u003e6.2%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 7. Patented and Design-Protected Intellectual Property Portfolio\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Protects the core technology (bilateral stimulation, leadless design) from direct infringement, securing future margins. The Genio System 2.1 received FDA approval on \u003cstrong\u003e08\/08\/2025\u003c\/strong\u003e for use in the treatment of moderate to severe Obstructive Sleep Apnea (OSA).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Most MedTech firms have IP, but the specific patents covering the Genio's unique features are rare. The portfolio includes specific U.S. Patent Nos. asserted against competitors: \u003cstrong\u003e8,700,183\u003c\/strong\u003e, \u003cstrong\u003e9,415,215\u003c\/strong\u003e, and \u003cstrong\u003e9,415,216\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIP Metric (As of December 31, 2023)\u003c\/th\u003e\n\u003cth\u003eCount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Granted or Pending Patent Applications\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e199\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIssued or Allowed U.S. Patents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e54\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Pending Patent Applications\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e40\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. Pending Patent Applications\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Trademark Registrations\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e6\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Patents provide legal barriers that stop direct copying for the life of the patent. The company actively defends this portfolio, filing a patent infringement lawsuit against Inspire Medical Systems, Inc.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. The company actively defends and builds upon this portfolio, as seen in its R\u0026amp;D structure and legal actions. The commitment is reflected in the increasing investment in Research and Development activities.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric (EUR)\u003c\/th\u003e\n\u003cth\u003eFull Year 2023\u003c\/th\u003e\n\u003cth\u003eFull Year 2024\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Research and Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€26.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€34.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D Expenses (Q4)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€7.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€11.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP Costs (Component of R\u0026amp;D)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€941,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€44,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. Patents are the classic source of long-term advantage in technology, supported by the company's pursuit of legal remedies to protect its proprietary, minimally invasive Genio system.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe Genio system is the first neurostimulation system for OSA to include a battery-free and leadless neurostimulator capable of delivering bilateral HGNS.\u003c\/li\u003e\n\u003cli\u003eThe company relies on a combination of patent(s) (applications), trademarks, designs and trade secrets to protect its technology.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 8. Strong European Commercial Foundation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eProvides a stable, existing revenue base (CE marked since \u003cstrong\u003e2019\u003c\/strong\u003e) to fund the expensive U.S. scale-up, with revenue growing \u003cstrong\u003e74%\u003c\/strong\u003e year-over-year in Q2 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eMedium. Many startups lack a mature, revenue-generating market to lean on during U.S. entry.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eLow. Competitors would need to build this market presence from scratch, which takes years.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh. The company manages both mature European sales and nascent U.S. launch simultaneously.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained. The established European footprint de-risks the overall business model significantly.\u003c\/p\u003e\n\u003cp\u003eEuropean Commercial Foundation Metrics (Q2 2025 Preliminary\/Reported Data):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eDate\/Period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCE Mark Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2019\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eGenio® System Approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue Growth (YoY)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€1.34 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e63.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ2 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, Financial Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€43.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSupporting Financial Context:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue for the second quarter ending June 30, 2025, was \u003cstrong\u003e€1.3 million\u003c\/strong\u003e, compared to \u003cstrong\u003e€0.8 million\u003c\/strong\u003e for the second quarter ending June 30, 2024.\u003c\/li\u003e\n\u003cli\u003eCost of goods sold for Q2 2025 was \u003cstrong\u003e€490,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eOperating expenses for Q2 2025 were anticipated to be approximately \u003cstrong\u003e€20.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eNyxoah S.A. (NYXH) - VRIO Analysis: 9. Conservative Financial Leverage Profile\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Low debt-to-equity ratio of \u003cstrong\u003e41.53%\u003c\/strong\u003e (as of June 2025) means the company is less burdened by fixed interest payments during this high-burn phase.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Medium. Many growth-stage MedTech firms rely heavily on debt; Nyxoah has leaned more on equity financing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Medium. It reflects past financing decisions, which can be replicated but also shows financial discipline.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High. Management has consciously chosen a less leveraged path, providing financial flexibility.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. While a strength now, future financing needs could force them to take on more debt.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinancial Data Snapshot:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePeriod\/Date\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.84 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt-to-Equity Ratio\u003c\/td\u003e\n\u003ctd\u003eMRQ (June 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e41.53%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Financial Assets\u003c\/td\u003e\n\u003ctd\u003eJune 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€43.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Financial Assets\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€22.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Burn (Net Cash Used in Operations)\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€20.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Operating Loss\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€24.4 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eQ3 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e€2.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey Financial Statistics:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash position decreased by \u003cstrong\u003e€20.5 million\u003c\/strong\u003e from the end of Q2 2025 (€43.0 million) to the end of Q3 2025 (€22.5 million).\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Margin was \u003cstrong\u003e60.5%\u003c\/strong\u003e, compared to 62.0% in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eSelling, General and Administrative (SG\u0026amp;A) expenses for Q3 2025 were \u003cstrong\u003e€12.7 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eResearch and Development (R\u0026amp;D) expenses for Q3 2025 were \u003cstrong\u003e€12.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFinancing commitments secured in November 2025 totaled up to \u003cstrong\u003e$77 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow View Incorporating Q3 2025 Burn Rate\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe Q3 2025 operating cash burn rate of \u003cstrong\u003e€20.5 million\u003c\/strong\u003e over 13 weeks implies a weekly cash burn of approximately \u003cstrong\u003e€1.58 million\u003c\/strong\u003e (€20.5 million \/ 13 weeks). The 13-week projection would commence from the cash balance at the end of Q3 2025, which was \u003cstrong\u003e€22.5 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThe following table outlines the known cash flow components relevant to the projection period, assuming the Q3 burn rate is representative of the initial weeks:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeriod (Week)\u003c\/td\u003e\n\u003ctd\u003eBeginning Cash Balance\u003c\/td\u003e\n\u003ctd\u003eEstimated Net Cash Flow\u003c\/td\u003e\n\u003ctd\u003eEnding Cash Balance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWeek 1 - Week 13 (Projection)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e€22.5 million\u003c\/strong\u003e (As of Sept 30, 2025)\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e-€1.58 million\u003c\/strong\u003e per week\u003c\/td\u003e\n\u003ctd\u003eTo be determined by weekly actuals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516223447189,"sku":"nyxh-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/nyxh-vrio-analysis.png?v=1740200993","url":"https:\/\/dcf-model.com\/fr\/products\/nyxh-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}